Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy.
Checked against the public recordLast updated Oct 21, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 3
- Sponsor
- Mirati Therapeutics Inc.
- Interventions being studied
- Biological: Nivolumab; Drug: Sitravatinib; Drug: Docetaxel
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Diagnosis of Non-Squamous Non-Small Cell Lung Cancer * Receipt of at least one but not more than two prior treatment regimens in the advanced setting * Prior treatment with PD-1/PD-L1 checkpoint inhibitor therapy and platinum-based chemotherapy in combination or in sequence (i.e., platinum-based chemotheraphy followed by checkpoint inhibitor therapy) * Most recent treatment regimen must have included a checkpoint inhibitor therapy with radiographic disease progression on or after treatment * Candidate to receive docetaxel as second or third line therapy Exclusion Criteria: * Uncontrolled brain metastases * Tumors that have tested positive for EGFR, ROS1, ALK mutations, or ALK fusions * Unacceptable toxicity with prior checkpoint inhibitor therapy * Receipt of systemic anti-cancer therapy post checkpoint inhibitor therapy, other than maintenance chemotherapy * Impaired heart function
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Local Institution - 005-164Birmingham, Alabama
- Clearview Cancer Institute - HuntsvilleHuntsville, Alabama
- Palo Verde Cancer Specialists - GlendaleGlendale, Arizona
- The Oncology Institute of Hope & Innovation - TucsonTucson, Arizona
- Yuma Regional Medical CenterYuma, Arizona
- Local Institution - 005-174Jonesboro, Arkansas
- NEA Baptist Fowler Family Center for Cancer CareJonesboro, Arkansas
- Highlands Oncology Group - SpringdaleSpringdale, Arkansas
- Comprehensive Blood and Cancer Center - BakersfieldBakersfield, California
- Local Institution - 005-118Beverly Hills, California
- Local Institution - 005-171Fresno, California
- Providence Medical Foundation - Virginia K. Crosson Cancer Center - FullertonFullerton, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 21, 2025. Always confirm current availability with the study team.